Veru Inc. Engages Investors at BTIG Virtual Biotechnology Conference and Makes Progress with Enobosarm Clinical Trials for High-Quality Weight Loss’
Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company headquartered in Miami, Florida, is at the forefront of innovation in the healthcare sector. On July 29, 2024, the company announced its participation in the upcoming BTIG Virtual Biotechnology Conference, scheduled for August 5, 2024. This event will provide an opportunity for Veru to engage in one-on-one meetings with investors, highlighting its commitment to transparency and communication with stakeholders as it continues to develop cutting-edge medicines.
Focused on preserving muscle while promoting high-quality weight loss, oncology treatments, and addressing viral-induced acute respiratory distress syndrome, Veru is dedicated to addressing complex health challenges through biomedical innovation. The company recently made
Comments